Guidelineonsafetyandresiduedatarequirementsforpharmaceuticalveterinarymedicinalproductsintendedforminoruseorminorspecies(MUMS)/limitedmarket
2017-01-03
/
指导原则
欧洲
现行有效
/
欧洲药品管理局（EMEA）
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-10
-
2026-08-10
-
摩熵咨询 35 26
-
摩熵咨询 28 37
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29
最新指导原则
-
国家卫生健康委办公厅关于印发医疗机构卒中中心建设与管理指导原则(2026年版)的通知
2026-07-28
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
-
国家药监局器审中心关于发布心磁信号采集设备注册审查指导原则等57项指导原则的通告(2026年第24号)
2026-07-21
-
国家药监局药审中心关于发布<生物制品批准后药学变更管理方案技术指导原则>的通告(2026年第41号)
2026-07-17
-
国家药监局器审中心关于发布<中心静脉导管注册审查指导原则(2026年修订版)>的通告(2026年第23号)
2026-07-15
-
国家药监局药审中心关于发布<基因治疗药品范围和归类技术指导原则(2026年版)>的通告(2026年第40号)
2026-07-03
-
国家药监局药审中心关于发布<细胞治疗药品范围和归类技术指导原则(2026年版)>的通告(2026年第39号)
2026-07-03
-
国家药监局器审中心关于发布<基于高通量测序法的胎儿染色体非整倍体(t21、t18、t13)检测试剂盒注册审查指导原则(2026年修订版)>等2项注册审查指导原则的通告(2026年第22号)
2026-07-02
-
国家药监局关于发布<脑机接口医疗器械产品分类界定指导原则><脑机接口医疗器械通用名称命名指导原则>等2项医疗器械产品指导原则的通告(2026年第24号)
2026-06-30
-
关于公开征求<以患者为中心创新药研发统计方法学技术指导原则(征求意见稿)>意见的通知
2026-06-25
-
关于公开征求<斑秃治疗药物临床试验技术指导原则>(征求意见稿)意见的通知
2026-06-24
-
国家药监局器审中心关于发布医用磁共振成像系统注册审查指导原则(2026年修订版)的通告(2026年第21号)
2026-06-23
-
国家药监局器审中心关于发布<hla-b*58:01基因检测试剂注册审查指导原则>的通告(2026年第17号)
2026-06-15
-
国家药监局药审中心关于发布<预防用mrna疫苗临床试验技术指导原则(试行)>的通告(2026年第38号)
2026-06-01
-
国家药监局药审中心关于发布<关于开发适宜药品包装规格的指导原则>的通告(2026年第37号)
2026-06-01
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-10
-
2026-08-10
-
2026-08-10
-
摩熵咨询 20 7
-
摩熵咨询 34 24
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
同部门最新指导原则
-
Direct healthcare professional communication (DHPC) : Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi)
2023-03-30
-
Overview of comments received on ICH guideline Q5A (R2) on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin
2023-03-27
-
Acceptability of IU as abbreviation for International Units in the strength of human medicinal products
2023-03-24
-
Direct healthcare professional communication (DHPC) : Myalepta (metreleptin) 5.8 mg vial: shortage and mitigation plan
2023-03-14
-
Guideline on computerised systems and electronic data in clinical trials
2023-03-10
-
Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy
2023-03-01
-
Draft European Union herbal monograph on Cnicus benedictus L., herba
2023-02-16
-
EU/3/02/107: Public summary of positive opinion for orphan designation of purified bromelain for the treatment of partial deep dermal and full thickness burns
2023-02-15
-
Concept paper on revision of the ‘Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products / traditional herbal medicinal products’
2023-02-14
-
ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms - Step 2b
2023-02-07
-
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 5 - Revision 1
2023-02-06
-
Guideline on clinical evaluation of vaccines - Revision 1
2023-02-01
-
Overview of comments on 'Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance'
2022-12-16
-
Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients
2022-12-16
-
Overview of comments received on Draft Qualification Opinion of the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients
2022-12-16
同地域最新指导原则
-
concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients(关于制定支持儿科患者抗癌药物开发的概念验证数据反思文件的概念文件)
2026-03-13
-
overview of comments received on the draft reflection paper on the qualification of non-mutagenic impurities(关于非致突变性杂质界定问题的征求意见稿所获意见综述)
2026-03-13
-
eu implementation strategy of ich e2d(r1) guideline - post-approval safety data: definitions and standards for management and reporting of individual case safety reports(ich e2d(r1) 指导原则在欧盟的实施策略——上市后安全性数据:个例安全性报告的管理与报告定义及标准)
2026-03-06
-
guideline on the clinical investigation of medicinal products for the treatment of cystic fibrosis(治疗囊性纤维化药品临床研究指导原则)
2026-03-02
-
draft concept paper on the development of a reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products(关于制定微生态药物非临床研发与评价思考文件的概念性文件草案)
2026-03-02
-
overview of comments on ich m4q(r2) : guideline on the common technical document for the registration of pharmaceuticals for human use - quality - step 2b(关于ich m4q(r2)<人用药品注册通用技术文档——质量部分>指导原则(第2b阶段)的意见概述)
2026-02-20
-
overview of comments received on ich e20 guideline on adaptive designs for clinical trials (ema/chmp/ich/206586/2025)(关于ich e20<临床试验适应性设计指导原则>(ema/chmp/ich/206586/2025)的意见概述)
2026-02-16
-
concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of myasthenia gravis(关于制定重症肌无力治疗药物临床研究指导原则的必要性概念文件)
2026-02-13
-
concept paper on revision of the guidelines on good manufacturing practice for medicinal products - annex 6 manufacture of medicinal gases(关于修订<药品生产质量管理规范指南——附件6:医用气体生产>的概念文件)
2026-02-11
-
ich m15 guideline on general principles for model-informed drug development - step 5(ich m15<模型引导的药物研发通用原则指导原则>- 第5阶段)
2026-02-11
-
overview of comments received on q&a regarding co-processed excipients used in solid oral dosage forms h and v (ema/chmp/cvmp/qwp/422493/2024)(关于固体口服制剂h & v中使用的共处理辅料的问答意见概述(ema/chmp/cvmp/qwp/422493/2024))
2026-01-28
-
questions and answers regarding co-processed excipients used in solid oral dosage forms (h & v)(关于在固体口服制剂中使用的共处理辅料的问答(h & v))
2026-01-28
-
overview of comments received on on ich q3e guideline and supporting documentation for extractables and leachables (ema/chmp/ich/236669/2025 and ema/chmp/ich/236668/2025)(关于ich q3e指南和支持文件中提取物和浸出物的意见概述(ema/chmp/ich/236669/2025和ema/chmp/ich/236668/2025))
2026-01-28
-
overview of comments received on q&a regarding co-processed excipients used in solid oral dosage forms h and v (ema/chmp/cvmp/qwp/422493/2024)(关于口服固体制剂用共处理辅料(h和v)问答文件(ema/chmp/cvmp/qwp/422493/2024)的意见概述)
2026-01-28
-
overview of comments received on guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities(关于治疗下肢周围动脉闭塞性疾病药物临床研究指南的意见综述)
2026-01-27